Cepheid's Q4 Revenues Rise 30 Percent | GenomeWeb

This article has been updated with comments and additional information from the firm's conference call.

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its fourth-quarter revenues increased 30 percent on strong instrument and reagent growth.

The Sunnyvale, Calif.-based molecular diagnostics firm brought in total revenues of $49.2 million for the three-month period ended Dec. 31, compared to $37.8 million for the fourth quarter of 2008. The company easily beat analysts' consensus estimate of $45.4 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.